NEORAL by Novartis is clinical pharmacology cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. Approved for organ rejection in kidney, liver, heart allogeneic transplants and 2 more indications. First approved in 1997.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
NEORAL is a cyclosporine oral immunosuppressant approved for preventing organ rejection in kidney, liver, and heart transplants, as well as treating rheumatoid arthritis inadequately responsive to methotrexate. It works by potent, reversible inhibition of T-lymphocytes in the G0/G1 phase of the cell cycle, preferentially targeting T-helper cells and blocking interleukin-2 production.
Declining Part D spending and approaching loss of exclusivity signal contraction of brand team size and shift toward generic support or exit strategy planning.
CLINICAL PHARMACOLOGY Cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. Cyclosporine has been demonstrated to suppress some humoral immunity and to a…
Worked on NEORAL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moZero linked job postings reflect the product's mature, declining commercial stage with minimal hiring. Career opportunities are concentrated in defensive roles focused on market access, compliance, and managed care negotiations rather than growth-oriented positions.